Blockbuster weight loss and diabetes drugs Wigovy and Ozempic top the list of 15 drugs selected for a second round of federal price negotiations scheduled to begin this year, resulting in lower prices. will come into effect in 2027.
The first round of negotiations for 10 high-priced drugs concluded in August, resulting in prices between 38 and 79 percent below list prices. These negotiated prices go into effect in 2026 and are expected to save people with Medicare prescription drug coverage $1.5 billion in out-of-pocket costs.
“Last year, we proved that negotiating drug prices down is effective,” Health and Human Services (HHS) Secretary Xavier Becerra said in a statement. “We look forward to building on that track record in negotiating drug price reductions.” I’m going to go,” he said. 15 additional important medications for seniors. ”
A list of the 15 drugs in the next round, in the order provided by HHS, is below. About 5.3 million people with Medicare prescription drug coverage used at least one of these drugs between 2023 and 2024, according to the health department. Together, these drugs accounted for approximately $41 billion in total prescription drug coverage during that period, or approximately $1.4 billion. percent.
1 Ozempic; Libersus. Wegovy Weight Loss, Type 2 Diabetes 2 Trelegy Ellipta Asthma and COPD 3 Xtandi Prostate Cancer 4 Pomalyst Multiple Myeloma and Kaposi’s Sarcoma 5 Ibrance Breast Cancer 6 Ofev Idiopathic Pulmonary Fibrosis 7 Linzes IBS and Chronic Constipation 8 Calquence Blood Cancer 9 Austed; Austed XR Huntington’s Disease 10 Breo Ellipta Asthma and COPD 11 Tragenta Type 2 Diabetes 12 Xifaxan Diarrhea and Irritable Bowel Syndrome 13 Vreiler Mental Health and Mood Disorders 14 Janumet; Janumet XR Type 2 Diabetes 15 Otezla Psoriasis and Psoriatic Arthritis
Topping the list are three versions of the semaglutide drug sold by Novo Nordisk. Wegovy is used for weight loss and reducing the risk of cardiovascular disease. Ozempic, used for type 2 diabetes. Rybelsus is used for type 2 diabetes. As popular as the drug is, it is also expensive. Wegovy’s list price is around $1,350, while Ozempic’s list price is closer to $1,000.
